Nanocarriers for Therapeutics Delivery of Cardiovascular Disease
- By Fahima Dilnawaz1
-
View Affiliations Hide Affiliations1 Laboratory of Nanomedicine, Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar 751023, Odisha, India
- Source: Nanomedicinal Approaches Towards Cardiovascular Disease , pp 40-51
- Publication Date: July 2021
- Language: English
Nanocarriers for Therapeutics Delivery of Cardiovascular Disease, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789814998215/chapter-5-1.gif
Cardiovascular diseases are presently the leading cause of death worldwide. Prescribed drugs in terms of therapeutic modalities of clinical management have treated patients, but still a limitation exists. This administered drug displays unwanted health adversity due to the side effects. In this regard, the current focus has been drawn towards nanomedicine-based drug formulation, which illustrates better therapeutic ability, sustained release, bioavailability and less toxicity. To address this, various nanocarriers are developed and are being involved in and studied for clinical application. In this chapter, the potential application of different nanocarrier-based therapeutic delivery has been discussed.
-
From This Site
/content/books/9789814998215.chapter-5dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
